Alkermes plc Stock News

Alkermes price target lowered to $21 from $22 at Piper Sandler Piper Sandler ALKS

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu

In a report released today, Vamil Divan from Mizuho Securities maintained a Hold rating on Alkermes (ALKS), with a price target of $16.00. The company's

In a report released today, Vamil Divan from Mizuho Securities maintained a Hold rating on Alkermes ( ALKS – Research Report ), with a price target of $16.00 . The company’s shares closed last Tue

DUBLIN (AP) _ Alkermes PLC (ALKS) on Wednesday reported a loss of $38.7 million in its first quarter. The Dublin-based company said it had a loss of 24 cents per share. Earnings, adjusted for one-time

Shares of Alkermes (NASDAQ:ALKS) rose 0.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share increased 105.88% year over year to $0.01, which beat the es

Alkermes reports Q1 adjusted EPS 1c, consensus (6c) ALKS

Alkermes withdraws previous FY20 guidance due to COVID-19 impact ALKS

Alkermes Plc:

Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2020, and provided commentary related to the impact of the COVID-19 pandemic on the business.

Alkermes Plc (NASDAQ:ALKS) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 9,290,000 shares, an increase of 16.6% from the March

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) AstraZeneca plc (NYSE:...

Alkermes (NASDAQ:ALKS) is scheduled to announce Q1 earnings results on Wednesday, April 29th, before market open.The consensus EPS Estimate is -$0.05 (+70.6% Y/Y) and the consensus Revenue Estimate is

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.